Bree R Eaton1, Stephanie L Pugh2, Jeffrey D Bradley2, Greg Masters2, Vivek S Kavadi2, Samir Narayan2, Lucien Nedzi2, Cliff Robinson2, Raymond B Wynn2, Christopher Koprowski2, Douglas W Johnson2, Joanne Meng2, Walter J Curran2. 1. Winship Cancer Institute of Emory University, Atlanta, GA (BRE, WJCJr); NRG Oncology Statistics and Data Management Center, Philadelphia, PA (SLP); Washington University School of Medicine, St. Louis, MO (JDB, CR); Christiana Care/Helen Graham Medical Center, Newark, DE (GM); USON-Texas Oncology, Sugarland, TX (VSK); Michigan Cancer Research Consortium, Ann Arbor, MI (SN); University of Texas Southwestern Medical School, Dallas, TX (LN); University of Pittsburgh Medical Center, Pittsburgh, PA (RBW); Christiana Care Health System, Wilmington, DE (CK); Florida Radiation Oncology Group, Jacksonville, FL (DWJ); The Ottawa Hospital, Ottawa, ON, Canada (JM) brupper@emory.edu. 2. Winship Cancer Institute of Emory University, Atlanta, GA (BRE, WJCJr); NRG Oncology Statistics and Data Management Center, Philadelphia, PA (SLP); Washington University School of Medicine, St. Louis, MO (JDB, CR); Christiana Care/Helen Graham Medical Center, Newark, DE (GM); USON-Texas Oncology, Sugarland, TX (VSK); Michigan Cancer Research Consortium, Ann Arbor, MI (SN); University of Texas Southwestern Medical School, Dallas, TX (LN); University of Pittsburgh Medical Center, Pittsburgh, PA (RBW); Christiana Care Health System, Wilmington, DE (CK); Florida Radiation Oncology Group, Jacksonville, FL (DWJ); The Ottawa Hospital, Ottawa, ON, Canada (JM).
Abstract
BACKGROUND: The purpose of this analysis is to evaluate the effect of institutional accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC) on a phase III trial. METHODS:Patients with LA-NSCLC were randomly assigned to 60 Gy or 74 Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. Participating institutions were categorized as low-volume centers (LVCs) or high-volume centers (HVCs) according to the number of patients accrued (≤3 vs > 3). All statistical tests were two-sided. RESULTS: Range of accrual for LVCs (n = 195) vs HVCs (n = 300) was 1 to 3 vs 4 to 18 patients. Baseline characteristics were similar between the two cohorts. Treatment at a HVC was associated with statistically significantly longer overall survival (OS) and progression-free survival (PFS) compared with treatment at a LVC (median OS = 26.2 vs 19.8 months; HR = 0.70, 95% CI = 0.56 to 0.88, P = .002; median PFS: 11.4 vs 9.7 months, HR = 0.80, 95% CI = 0.65-0.99, P = .04). Patients treated at HVCs were more often treated with intensity-modulated RT (54.0% vs 39.5%, P = .002), had a lower esophageal dose (mean = 26.1 vs 28.0 Gy, P = .03), and had a lower heart dose (median = V5 Gy 38.2% vs 54.1%, P = .006; V50 Gy 3.6% vs 7.3%, P < .001). Grade 5 adverse events (AEs) (5.3% vs 9.2%, P = .09) and RT termination because of AEs (1.3% vs 4.1%, P = .07) were less common among patients treated at HVCs. HVC remained independently associated with longer OS (P = .03) when accounting for other factors. CONCLUSION: Treatment at institutions with higher clinical trial accrual volume is associated with longer OS among patients with LA-NSCLC participating in a phase III trial.
RCT Entities:
BACKGROUND: The purpose of this analysis is to evaluate the effect of institutional accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC) on a phase III trial. METHODS:Patients with LA-NSCLC were randomly assigned to 60 Gy or 74 Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. Participating institutions were categorized as low-volume centers (LVCs) or high-volume centers (HVCs) according to the number of patients accrued (≤3 vs > 3). All statistical tests were two-sided. RESULTS: Range of accrual for LVCs (n = 195) vs HVCs (n = 300) was 1 to 3 vs 4 to 18 patients. Baseline characteristics were similar between the two cohorts. Treatment at a HVC was associated with statistically significantly longer overall survival (OS) and progression-free survival (PFS) compared with treatment at a LVC (median OS = 26.2 vs 19.8 months; HR = 0.70, 95% CI = 0.56 to 0.88, P = .002; median PFS: 11.4 vs 9.7 months, HR = 0.80, 95% CI = 0.65-0.99, P = .04). Patients treated at HVCs were more often treated with intensity-modulated RT (54.0% vs 39.5%, P = .002), had a lower esophageal dose (mean = 26.1 vs 28.0 Gy, P = .03), and had a lower heart dose (median = V5 Gy 38.2% vs 54.1%, P = .006; V50 Gy 3.6% vs 7.3%, P < .001). Grade 5 adverse events (AEs) (5.3% vs 9.2%, P = .09) and RT termination because of AEs (1.3% vs 4.1%, P = .07) were less common among patients treated at HVCs. HVC remained independently associated with longer OS (P = .03) when accounting for other factors. CONCLUSION: Treatment at institutions with higher clinical trial accrual volume is associated with longer OS among patients with LA-NSCLC participating in a phase III trial.
Authors: Eric C Schneider; Jennifer L Malin; Katherine L Kahn; Ezekiel J Emanuel; Arnold M Epstein Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544
Authors: Todd A Pezzi; David L Schwartz; Abdallah S R Mohamed; James W Welsh; Ritsuko U Komaki; Stephen M Hahn; Boris Sepesi; Christopher M Pezzi; Clifton D Fuller; Stephen G Chun Journal: JAMA Oncol Date: 2018-08-09 Impact factor: 31.777
Authors: Saif S Ahmad; Marka R Crittenden; Phuoc T Tran; Paul G Kluetz; Gideon M Blumenthal; Helen Bulbeck; Richard D Baird; Kaye J Williams; Tim Illidge; Stephen M Hahn; Theodore S Lawrence; Patricia A Spears; Amanda J Walker; Ricky A Sharma Journal: Clin Cancer Res Date: 2018-11-29 Impact factor: 12.531
Authors: Nan Li; Ruben Carmona; Igor Sirak; Linda Kasaova; David Followill; Jeff Michalski; Walter Bosch; William Straube; Loren K Mell; Kevin L Moore Journal: Int J Radiat Oncol Biol Phys Date: 2016-10-13 Impact factor: 7.038
Authors: Martin J Edelman; Chen Hu; Quynh-Thu Le; Jessica S Donington; Warren D D'Souza; Adam P Dicker; Billy W Loo; Elizabeth M Gore; Gregory M M Videtic; Nathaniel R Evans; Joseph W Leach; Maximilian Diehn; Steven J Feigenberg; Yuhchyau Chen; Rebecca Paulus; Jeffrey D Bradley Journal: J Thorac Oncol Date: 2017-06-16 Impact factor: 15.609
Authors: Jeffrey D Bradley; Chen Hu; Ritsuko R Komaki; Gregory A Masters; George R Blumenschein; Steven E Schild; Jeffrey A Bogart; Kenneth M Forster; Anthony M Magliocco; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Clifford G Robinson; Raymond B Wynn; Christopher D Koprowski; Michael R Olson; Joanne Meng; Rebecca Paulus; Walter J Curran; Hak Choy Journal: J Clin Oncol Date: 2019-12-16 Impact factor: 44.544